Compare Stocks: ENTA, GHRS, CALT, and CRON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.19 -0.5%	$3.25	$2.28 ▼ $3.61	$1.17B	0.9	1.27 million shs	641,298 shs
ENTA Enanta Pharmaceuticals	$11.28 -2.0%	$13.04	$10.20 ▼ $17.15	$328.04M	0.96	209,557 shs	107,249 shs
GHRS GH Research	$18.60 -1.3%	$26.70	$12.04 ▼ $31.44	$1.28B	1.32	300,437 shs	162,860 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	-0.31%	-2.74%	+1.91%	+16.79%	+25.49%
ENTA Enanta Pharmaceuticals	-6.34%	-5.34%	-11.11%	-12.93%	+0.26%
GHRS GH Research	-5.84%	-12.41%	-30.70%	-29.98%	+45.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.19 -0.5%	$3.25	$2.28 ▼ $3.61	$1.17B	0.9	1.27 million shs	641,298 shs
ENTA Enanta Pharmaceuticals	$11.28 -2.0%	$13.04	$10.20 ▼ $17.15	$328.04M	0.96	209,557 shs	107,249 shs
GHRS GH Research	$18.60 -1.3%	$26.70	$12.04 ▼ $31.44	$1.28B	1.32	300,437 shs	162,860 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	-0.31%	-2.74%	+1.91%	+16.79%	+25.49%
ENTA Enanta Pharmaceuticals	-6.34%	-5.34%	-11.11%	-12.93%	+0.26%
GHRS GH Research	-5.84%	-12.41%	-30.70%	-29.98%	+45.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRON Cronos Group	2.60	Moderate Buy	$2.30	-28.01% Downside
ENTA Enanta Pharmaceuticals	2.50	Moderate Buy	$19.00	67.40% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	140.64% Upside

Current Analyst Ratings Breakdown

Latest ENTA, GHRS, CALT, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
9/28/2026	CRON Cronos Group	TD Securities Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/23/2026	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00
9/22/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
8/26/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	GHRS GH Research	New Street Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$65.00
8/10/2026	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/7/2026	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$34.00 ➝ $40.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRON Cronos Group	$146.59M	8.03	$0.01 per share	256.04	$3.00 per share	1.07
ENTA Enanta Pharmaceuticals	$65.32M	5.06	N/A	N/A	$3.03 per share	3.75
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRON Cronos Group	-$9.45M	$0.20	15.98	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)

Latest ENTA, GHRS, CALT, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CRON Cronos Group	$0.03	N/A	N/A	N/A	$49.47 million	N/A
11/5/2026	Q3 2026	GHRS GH Research	-$0.3122	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRON Cronos Group	N/A	16.18	15.25
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
GHRS GH Research	N/A	28.70	28.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CRON Cronos Group	8.71%
ENTA Enanta Pharmaceuticals	94.99%
GHRS GH Research	56.90%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CRON Cronos Group	7.80%
ENTA Enanta Pharmaceuticals	11.48%
GHRS GH Research	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CRON Cronos Group	610	368.54 million	339.80 million	Optionable
ENTA Enanta Pharmaceuticals	120	29.12 million	25.78 million	Optionable
GHRS GH Research	73	68.61 million	N/A	Optionable

ENTA, GHRS, CALT, and CRON Headlines

Recent News About These Companies

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026

October 9, 2026 | tipranks.com

GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

October 3, 2026 | americanbankingnews.com

GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts

October 3, 2026 | marketbeat.com

GH Research (NASDAQ:GHRS) Shares Up 5.7% - Here's Why

September 29, 2026 | marketbeat.com

GH Research (NASDAQ:GHRS) Stock Price Down 7% - What's Next?

September 24, 2026 | marketbeat.com

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

September 20, 2026 | seekingalpha.com

GH Research (NASDAQ:GHRS) Sees Large Volume Increase - Time to Buy?

September 17, 2026 | marketbeat.com

GH Research Files Q2 2026 Results and Updates Corporate Presentation

August 6, 2026 | tipranks.com

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Cours GH Research PLC

August 1, 2026 | zonebourse.comZ

Wells Fargo Initiates GH Research at Overweight With $44 Price Target

July 29, 2026 | finance.yahoo.com

Why Psychedelic stocks are surging today

July 16, 2026 | finance.yahoo.com

Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks

July 16, 2026 | msn.com

GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)

July 16, 2026 | msn.com

GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM

June 26, 2026 | tipranks.com

H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)

June 5, 2026 | insidermonkey.com

GH Research Announces Publication of Phase 2a Postpartum Depression Results

June 4, 2026 | globenewswire.com

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

May 20, 2026 | seekingalpha.com

Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans

May 16, 2026 | finance.yahoo.com

GH Research Launches $200 Million At-the-Market Share Offering With Stifel

May 14, 2026 | tipranks.com

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENTA, GHRS, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 10/13/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cronos Group NASDAQ:CRON

$3.18 -0.02 (-0.47%)

As of 03:15 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Enanta Pharmaceuticals NASDAQ:ENTA

$11.28 -0.24 (-2.05%)

As of 03:16 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

GH Research NASDAQ:GHRS

$18.60 -0.25 (-1.33%)

As of 03:16 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, GHRS, CALT, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, GHRS, CALT, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, GHRS, CALT, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, GHRS, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Enanta Pharmaceuticals NASDAQ:ENTA

GH Research NASDAQ:GHRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, GHRS, CALT, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, GHRS, CALT, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, GHRS, CALT, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, GHRS, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Enanta Pharmaceuticals NASDAQ:ENTA

GH Research NASDAQ:GHRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools